Inserm U1190

Translational Research for Diabetes

[Francois Pattou @francois_pattou]

Excited to share our latest study with @stefano_romeo76 , published in @NatureMedicine!
We uncover 2 distinct subtypes of MASH:
🔹 Liver-specific: Faster liver disease progression, lower CV risk.
🔹 Cardiometabolic: Higher CV/metabolic risks, incl. T2D.
https://t.co/TFVkvhgKML

[Inserm U1190 @InsermU1190]

New findings from U1190 team @CHU_Lille @univ_lille

[Nature Medicine @NatureMedicine]

Partitioning clustering based on clinical variables applied to multiple patients cohorts identifies two subtypes of #MASLD with different associations to #hepatic and #cardiovascular outcomes @francois_pattou @LilleInfinite
https://t.co/WPhOJpXsBN

[Nature Medicine @NatureMedicine]

Partitioning clustering based on clinical variables applied to multiple patients cohorts identifies two subtypes of #MASLD with different associations to #hepatic and #cardiovascular outcomes @francois_pattou @LilleInfinite
https://t.co/WPhOJpXsBN

[Inserm U1190 @InsermU1190]

Congratulations to Pr. François Pattou and Dr. Violeta Raverdy for this collaborative study with Pr. Stefano Romeo published in @NatureMedicine : https://t.co/qMNAg96Wm1 👏🏻👏🏻👏🏻

[Inserm U1190 @InsermU1190]

Retrouvez l’histoire de Dominique, une de nos patientes greffées d’îlots il y a 11 ans au CHU de Lille : https://t.co/hHp4GQgnIV

[Inserm U1190 @InsermU1190]

Retrouvez l’interview France Culture de notre Pr. Marie-Christine Vantyghem sur le diabète de type 1 et la greffe d’îlots : https://t.co/3kQPIBYVUK

[Francois Pattou @francois_pattou]

Our recent #Diabetes publication shows reducing intestinal SGLT1 expression lowers early glucose levels post-meal, suggesting a new way to manage T2D.
https://t.co/3BINUhwY96

[Recherche - Université de Lille @RechercheUlille]

🚀Félicitations à @PreciDIABCenter pour le label " Équipe FRM 2023 " sur leur projet de médecine de précision en chirurgie métabolique !

Hier, la #RTD a eu l'honneur de recevoir Thierry Lhermitte, parrain de la @FRM_officiel.

👉https://t.co/lXbAOp0xx8

📸Photos de #PreciDiab.

[Mikael Chetboun @mikachet]

Very proud of our colleague @MaanaouiMehdi, who defended today his PhD like a champ on islet transplantation in diabetic patients with renal failure. A great article in prospect that will be much talked about! #welcomeinthePhDfamily #mbappeduglomerule @InsermU1190

[ESOTtransplant @ESOTtransplant]

Unmissable Opportunity #EPITAsymposium
Don't miss out on the chance to present your research!

The abstract submission deadline is set for 23 November at 23:59 CET, and 𝘁𝗵𝗲𝗿𝗲 𝘄𝗼𝗻'𝘁 𝗯𝗲 𝗮𝗻𝘆 𝗲𝘅𝘁𝗲𝗻𝘀𝗶𝗼𝗻𝘀.

Be part of something great!
https://t.co/qx0GzCPZF8

[Mikael Chetboun @mikachet]

For those who asked us to see Felix Gretarsson @hrFelix intervention during EUROPEAN SOCIETY FOR SURGICAL RESEARCH @EssrMedia congress, please follow him on #YouTube here
https://t.co/3VL405rZpS
Outstanding man, husband, father & speaker

[Mehdi Maanaoui @MaanaouiMehdi]

Check out the last article from the lab @InsermU1190 @CHU_Lille @univ_lille @mikachet @francois_pattou 😁
Cognitive Outcome After Islet Transplantation : Transplantation Direct https://t.co/bbWS6lquFU

[Mikael Chetboun @mikachet]

✌ We're thrilled to share our newest article, just published online
👉 https://t.co/1yA1yKZYZw
#research #science #diabetes #transplantation @UFR3S_ULille @CHU_Lille @univ_lille

[Mehdi Maanaoui @MaanaouiMehdi]

So pleased and proud to share the last article in @TheLancetEndo from @InsermU1190 @francois_pattou lab: islet transplantation and primary graft function 👉 collaborative work with the CITR registry, led by the one and only @mikachet 🔥 https://t.co/ENoesJbjXQ

[Mehdi Maanaoui @MaanaouiMehdi]

Inspiring @InsermU1190 @CHU_Lille @univ_lille

[PreciDIAB @PreciDIABCenter]

📢 A l'occasion de la #JournéeMondialedelObesite, le journal @Lille_actu fait le point avec le Pr @francois_pattou sur l'#obésité dans la région des @hautsdefrance et l'interroge sur les #traitements pour lutter contre l'obésité? 👇
@CHU_Lille
https://t.co/PTm0B81BLA

[Breakthrough T1D @BreakthroughT1D]

BREAKING: The U.S. Food and Drug Administration (FDA) authorized the @tidepool_org Loop, an automated insulin dosing app intended for the management of type 1 diabetes (T1D). (1/3)

[Mikael Chetboun @mikachet]

The KA IAK study. An outstanding presentation from our bro ⁦@MaanaouiMehdi⁩ ⁦@InsermU1190⁩ #trepid

[ESOTtransplant @ESOTtransplant]

The role of social media in transplantation masterfully 👏 presented by @Aimen_Amer
& @MaanaouiMehdi #ESOT_EPITA #TransplantTwitter

[Mikael Chetboun @mikachet]

And our first gentleman ⁦@MaanaouiMehdi⁩ ⁦@InsermU1190⁩ ⁦@francois_pattou⁩